# Tislelizumab in Combination With Bevacizumab and Capecitabine in Advanced Solid Tumors With Evaluation in Immunotherapy-Resistant and Central Nervous System Dis

Source: https://onco.cc/trials/nct07681297/  
OnCo record `nct07681297` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of tislelizumab, bevacizumab and capecitabine in triple-negative breast cancer, run by National University Hospital, Singapore, not yet recruiting.

## Summary

Tislelizumab in Combination With Bevacizumab and Capecitabine in Advanced Solid Tumors With Evaluation in Immunotherapy-Resistant and Central Nervous System Disease is a phase 1/2, interventional study registered as NCT07681297 by National University Hospital, Singapore, with a registry enrolment figure of 154 participants, started 2026-08 and due to reach its primary completion in 2028-08. Interventions recorded: Tislelizumab + Bevacizumab + Capecitabine. Conditions listed: Advanced Solid Tumor Cancer; Triple-Negative Breast Cancer (TNBC); CNS Disease; Breast Cancer. Triple-negative eligibility wording from the registry: "TNBC Cohort Inclusion Criteria". Sites: Singapore. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Also known as: TIBEC
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT07681297
- Phase: 1/2
- Setting: Phase Ib/II Study of Tislelizumab in Combination With Bevacizumab and Capecitabine in Advanced Solid Tumors With Evaluation in Immunotherapy-Resistant and Central Nervous System Disease (TIBEC)
- Sponsor: National University Hospital, Singapore
- Enrolled: 154

## Sources

- ClinicalTrials.gov NCT07681297: https://clinicaltrials.gov/study/NCT07681297

## Connected records

- cancers: [Metastatic triple-negative breast cancer](https://onco.cc/cancers/tnbc-metastatic/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Bevacizumab](https://onco.cc/drugs/bevacizumab/), [Capecitabine](https://onco.cc/drugs/capecitabine/), [Tislelizumab](https://onco.cc/drugs/tislelizumab/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07681297.json